With the COVID-19 pandemic wreaking havoc globally, the race for a viable vaccine has become more critical than ever before. The latest BBC Health News on COVID-19 vaccines highlights the advances being made in this area and gives hope to millions of people worldwide.
The Importance of Vaccines
The primary benefit of vaccines is to prevent or reduce the impact of infectious diseases. Vaccines work by stimulating the immune system to build up antibodies against a particular disease. This immunity decreases the likelihood of contracting the disease or reduces the severity of the symptoms. Vaccines save countless lives every year, and with the COVID-19 pandemic, the need for a vaccine has become more pressing than ever before.
Current Status of COVID-19 Vaccines
According to recent BBC Health News, there are over 100 COVID-19 vaccines under development globally. Among these vaccines, four have entered the final stage of clinical trials, known as phase III, which involves testing the vaccine on tens of thousands of people to determine its effectiveness and side effects. Some of the top COVID-19 vaccines in phase III clinical trials include:
1. Pfizer and BioNTech
Pfizer and BioNTech’s vaccine, BNT162b2, showed an efficacy rate of 95% in their phase III trials. The vaccine uses a messenger RNA (mRNA) technique to provoke an immune response. The mRNA technique allows for the vaccine’s speedy development, as compared to traditional vaccines, and stimulates the body to produce specific proteins to train the immune system on how to tackle the virus.
2. Moderna
Moderna’s vaccine, mRNA-1273, showed an efficacy rate of 94.5% in their phase III trials. The vaccine also employs the mRNA technique and requires storage at -20°C, unlike Pfizer and BioNTech’s vaccine, which needs to be stored at -70°C.
3. AstraZeneca and Oxford University
The AstraZeneca and Oxford University vaccine, AZD1222, uses a non-replicating viral vector approach to create immune responses. The vaccine showed an average efficacy rate of 70%, according to the initial analysis of its phase III trials in Brazil and the UK.
4. Johnson & Johnson
Johnson & Johnson’s vaccine, Ad26.COV2.S, uses a viral vector technique to induce an immune response. The vaccine showed a 72% efficacy rate in the USA and 66% rate globally during its phase III trials.
Final Thoughts
In conclusion, the latest BBC Health News on COVID-19 vaccines presents hope to the world. The progress been made in developing vaccines is commendable, and it is crucial to adopt a vaccination strategy that can reach all the corners of the world. Although the efficacy of the vaccines varies, any reduction in severe disease and deaths will be a win for humanity in the fight against COVID-19.
(Note: Do you have knowledge or insights to share? Unlock new opportunities and expand your reach by joining our authors team. Click Registration to join us and share your expertise with our readers.)
Speech tips:
Please note that any statements involving politics will not be approved.